Read our latest updates & insights

Prestige Biopharma announces it is set for an IPO in early February 2021. The IPO is expected to be worth US $348 million, with the majority of the funds to be reinvested in R&D.

Celltrion announces it has submitted an investigational new drug application for Ph III trials of CT-P41 (proposed denosumab biosimilar).

Kamada announces it has entered into agreements with two undisclosed international pharmaceutical companies to commercialise three biosimilar product candidates in Israel.

A new study reviews the use of rituximab as an alternative treatment option for the management of multiple sclerosis (MS). While not approved for MS, there is evidence of significant off-label usage of rituximab for the treatment of MS in some Northern European countries.

ADQ announces it will acquire Pharmax Pharmaceuticals, as well as investing in a minority stake in Biocon Biologics.

The Centre for Biosimilars reported a study presented at the 2020 San Antonio Breast Cancer Symposium found strong uptake of Amgen’s Kanjinti® (biosimilar trastuzumab) in Europe.

Alvotech announces it has broken ground on the extension to its high-tech centre in Reykjavik. The extension will house biosimilar development, drug refills, offices and warehouses, and is expected to be completed by the end of 2022.